Hence, drugs that can induce the upregulation of ARE-mediated expression of phase II detoxifying antioxidant enzymes via the Nrf2/ARE pathway would be a promising approach for neuroprotection in PD and stroke [21,22]. Here, GABPA is linked to Parkinson disease.